September 3rd, 2021

Commissioner Janet Woodcock
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993

Dear Commissioner Woodcock,

Thank you for your ongoing efforts to protect public health, particularly during this critical stage of the COVID-19 pandemic. We are writing about the draft guidance on drug products labeled as homeopathic as issued by the Food and Drug Administration (FDA or Agency) in 2017 and revised in 2019. We understand that the FDA is concerned about products labeled as homeopathic that push the envelope, prompting the Agency to reevaluate its regulatory approach to keep them within the appropriate guardrails of traditional homeopathic drugs. Unfortunately, the guidance has disproportionately impacted manufacturers who produce safe, genuine homeopathic products, which in turn has made a growing number of these medicines less accessible, if not entirely unavailable, to consumers who rely on them.

Since 1938 until 2017, the FDA consistently recognized the distinction between pharmaceutical and homeopathic drugs, and Congress has repeatedly reaffirmed this distinction as set forth in the Food, Drug, and Cosmetic Act. Most recently in 2020, Congress passed the Coronavirus Aid, Relief, and Economic Security (CARES) Act, which exempts homeopathic drugs from review under its provisions regarding pharmaceutical drugs. In 1938, the FDA supported the decision to recognize the Homeopathic Pharmacopoeia of the United States and its supplements as the official compendium of standards and monographs for homeopathic drug ingredients giving the Agency the tools to regulate homeopathic drugs as a unique and separate category of drugs. On several occasions the FDA has commented on this distinction as set forth by Congress, and the Agency’s policies have been in adherence with the law which, as the FDA stated in 1988, “gives no premarket review of true homeopathic dilutions.”

This distinction has previously allowed the FDA to enforce standards that separate and safeguard legitimate homeopathic products while permitting swift action against products that are adulterated, misbranded, or improperly labeled as homeopathic. It helps to protect consumers, provides manufacturers with a clear pathway to market their products, and ensures access to products which meet homeopathic standards for quality and purity.

However, the draft guidance outlines enforcement priorities that do not distinguish between products that meet homeopathic standards and those that are adulterated, misbranded, or improperly labeled as homeopathic. Under this guidance, manufacturers who comply with standards for quality, purity, and proper dilution are subject to enforcement action for products...
which are nontoxic by their very nature when made according to those standards. Additionally, the draft guidance no longer references the framework by which homeopathic manufacturers can legally market their products without risk of enforcement action, raising concerns about the stability of the market and the availability of homeopathic drug products among our constituents.

In congruence with both the 2021 and 2022 Appropriations report in which Congress “urges FDA to consider the views of patients in finalizing its draft guidance,” we are writing to understand how the FDA intends to utilize and adhere to the framework established by Congress as well as the Agency in order to protect consumers and ensure access to the products that meet homeopathic standards for quality and purity. Thank you again for your ongoing work to improve access to safe and affordable healthcare and thank you for your full and fair consideration of this inquiry.

Sincerely,

Ro Khanna
Member of Congress

Martin Heinrich  Dwight Evans  Lisa McClain
United States Senator  Member of Congress  Member of Congress

Mike Lee  Brian Fitzpatrick  Joe Neguse
United States Senator  Member of Congress  Member of Congress

Andy Biggs  Paul Gosar  Ralph Norman
Member of Congress  Member of Congress  Member of Congress

Gus Bilirakis  Glenn Grothman  Chellie Pingree
Member of Congress  Member of Congress  Member of Congress

Jamaal Bowman  Diana Harshbarger  Jamie Raskin
Member of Congress  Member of Congress  Member of Congress

Tony Cárdenas  Jaime Herrera Beutler  Matt Rosendale
Member of Congress  Member of Congress  Member of Congress

John Carter  Andy Levin  Thomas R. Suozzi
Member of Congress  Member of Congress  Member of Congress

Antonio Delgado  Nicole Malliotakis  John Yarmuth
Member of Congress  Member of Congress  Member of Congress